Hereditary fructose intolerance (HFI) is an inborn error ofmetabolism caused by aldolase B deficiency. The aldolase B gene has been cloned and the following mutations causing HFI have been identified: A149P (a G--C transversion in exon 5), A174D (a C--A transversion in exon 5), L288AC (a base pair deletion in exon 8), and N334K (a G--C transversion in exon 9). We have investigated the occurrence of these mutations in 11 Italian patients affected by HFI using PCR and hybridisation to specific oligomers.
Abstract
Hereditary fructose intolerance (HFI) is an inborn error ofmetabolism caused by aldolase B deficiency. The aldolase B gene has been cloned and the following mutations causing HFI have been identified: A149P (a G--C transversion in exon 5), A174D (a C--A transversion in exon 5), L288AC (a base pair deletion in exon 8), and N334K (a G--C transversion in exon 9). We have investigated the occurrence of these mutations in 11 Italian patients affected by HFI using PCR and hybridisation to specific oligomers.
We found that four patients were homozygous for the A149P mutation, two patients were homozygous for the A174D mutation, three patients were compound heterozygotes for both the A149P and A174D mutations, one patient was homozygous for the N334K mutation, and one patient did not show any of the reported mutations (HFI diagnosis carried out by aldolase B assay). The L288AC mutation has not been found in this survey. The first mutation is a G--C transversion in exon 5 resulting in an amino acid substitution Ala--Pro at position 149 of the protein (A149P). This mutation alters the substrate binding site of aldolase B, dramatically reducing its activity. A further mutation (A174D) is also a transversion C--A in exon 5, which results in a Ala--Asp substitution at position 174. A single base pair deletion (L288AC) has been identified in exon 8 causing a frameshift with a premature stop codon. Finally, a G-+C transversion has been found in exon 9, which results in an Asn-*Lys substitution at position 334 of the protein (N334K).
We have used the DNA polymerase chain reaction (PCR)6 to analyse directly the A149P, A174D, L288AC, and N334K mutations in 11 unrelated Italian patients affected by HFI.
Materials and methods DNA from peripheral blood of 11 HFI patients from 11 unrelated Italian families was prepared by conventional methods. A 322 bp region of exon 5, containing the mutation site, was amplified using 30 cycles of DNA PCR as follows: 1 1tg of genomic DNA was mixed with 100 Wd PCR reaction buffer. Reaction temperatures were: denaturing at 93°C for two minutes, annealing at 410C for two minutes, and extension at 71°C for two minutes using Taq DNA polymerase (Cetus, Perkin-Elmer, USA). Sequences for exon 5 were 5'CCC-TTTATTAGAAGCCCATG3' and 5'GGTCCATTTGTAGTTATAGT3'. Amplified DNA was electrophoresed on a 1 2% agarose gel and Southern blotted according to standard procedures. Filters were then hybridised to two different oligomers carrying either the wild (A149) or the mutant (149P) sequence: (A149) 5'AAGTGGCGTGCTG-TGCTGA3' and (149P) 5'AAGTGGCGTCCTG-TGCTGA3' (fig 1) . Filters were then rehybridised to show the presence of the A174D mutation using oligomers identifying either the wild type (A174) or the mutant (A174D) sequence: (A174) 5'TCGCTACGC- AldolasefB mutations in Italianfamilies affected by hereditaryfructose intolerance sequence or the mutant sequence, gave the following results.
(1) Patients 2, 3, 4, and 8 are homozygous for the A149P mutation. All four were diagnosed on the basis of fructaldolase assays using homogenates of liver biopsy samples. (2) Patients 1, 5, and 9 are compound heterozygotes for the A149P and the A174D mutations and were diagnosed by enzymatic assay. (3) Patients 6 and 7 are homozygous for the A174D mutation. The former was diagnosed on the basis of the intravenous fructose tolerance test and the latter by enzymatic assay. (4) Patient 10, whose diagnosis was carried out by aldolase B enzymatic assay, does not show either the A149P or the A174D mutation. (5) Patient 11, whose diagnosis was made only on the basis of clinical signs, is homozygous for the mutation N334K. None of the patients was found to carry the L288AC mutation (data not shown).
Discussion
In this survey of Italian patients, A149P was found to be the most common mutation causing HFI (5O0/o of independent alleles), while the A174D mutation was found in 35% of the HFI alleles. Three patients were found to be compound heterozygotes for A149P and A174D and their respective parents thus carry one or other of these two prevalent mutant alleles.
The prevalence of the A149P mutation in Italy confirms in part results of a European collaborative study by Cross et al,4 in which nine independent Italian patients had been already investigated. The frequency of the A149P mutation was found to be greatest in northern European countries and lowest in Italy. On the other hand, A174D is relatively more frequent in HFI patients from southern Europe and appears to be more frequent in Italy. The L288AC mutation, found in two Sicilian patients, was not observed in the present study, thus suggesting that it may represent a private mutation or may have been carried by migration from elsewhere in the Mediterranean region. N334K, found in patient number 11 ( 
